A comparative review of Serracor vs Neprinol
In September of 2004 Arthur Andrew Medical contracted Specialty Enzymes (SEB) to help develop their systemic enzyme Neprinol. SEB is the American affiliate office of Cal India Foods. SEB was granted rights to produce the Neprinol formula for Arthur Andrew Medical until late 2009. Arthur Andrew Medical had begun to receive complaints regarding its Neprinol products that had the company very concerned. The staff at Arthur Andrew began receiving complaints from its consumers that the Neprinol product seemed substantially less effective. Arthur Andrew immediately launched a full third party investigation into these concerns, beginning with a full spectrum of assay testing for strength and potency.
Assay test results confirmed their suspicion. Originally Neprinol was developed at 500mg per capsule with a rated activity strength of no less than 15,000 FU's or Fibrinolytic Units. Assay testing in several categories reviled a 33% decrease in activity. Each capsule averaged less than 10,000 FU's and they were under-weighted at only 475mg. In summation the potency of the product had been decreased by 33% and an additional 5% of the actual material was missing from every capsule.
Speciality Enzymes aka (AST Enzymes) had been skimming a substantial amount of enzymes from the formula and pocketing the added profits at a cost to the consumer and Arthur Andrew Medical. It is these unethical and shady business practices that cost them, the Neprinol account and any future business agreements with Arthur Andrew Medical. Arthur Andrew Medical was originally willing to pay substantially more for the inclusion of Specialty Enzymes trademarked enzymes in their Neprinol formula. Prior to the indecent president and CEO of Specialty Enzymes Vic Rathi called Arthur Andrew Medical to inform them that he would be raising prices by 5% even during economic recession. His reasoning was that the dollar was currently worth less, and he would need to increase costs to compensate. Arthur Andrew Medical had substantially increased their raw material purchasing with Specialty Enzymes over the years and had received 1-2% discounts for higher volume purchases. A 5% increase on much larger purchases would more than negate any previous discounts in a matter of months. Specialty Enzymes whether it be greed or a lack of available liquid assets did not accept any credit terms or negotiate any leniency for the price adjustment and insisted on an upfront 50% cash payment 8-10 weeks prior to delivery of materials. Arthur Andrew Medical estimates the dilution of the Neprinol formula coupled with the removal of 5% of the actual materials equated to a theft of up to $300k over several runs. Arthur Andrew refunded several thousand dollars to dissatisfied customers in 2009 in an attempt to right the wrong. Arthur Andrew also issued an official apology letter to affected customers and offered significant discounts on the purchase of new Neprinol bottles once the formula had been restored to its original label claims.
Rather than demand that Specialty Enzymes immediately restore Neprinol to its original formula and refund the material costs, Arthur Andrew subsequently took its Neprinol formulation elsewhere, contracting with several highly reputable Japanese enzyme manufacturers and a few local suppliers in the US and Canada. The loss of business for Specialty Enzymes delivered a significant blow to their yearly enzyme sales. Later that year Specialty Enzymes decided to manufacture and market their own systemic enzyme formula. They named it Serracor and they claim it’s the original Neprinol formula. In fact, it is not the original Neprinol formula, but rather the diluted knock-off that many of Arthur Andrew Medical's customers originally complained about. Arthur Andrew Medical recently tested Serracor for potency. Assay tests revealed their suspicion, the FU rating was only 2/3 of its labeled rating. Consumers can easily tell the difference simply by weighing a capsule of Serracor, each capsule is on average only 475mg of the label that reads 500mg. Arthur Andrew was able to save a significant amount of money contracting new, more competitive and honest raw material manufactures.
Instead of pocketing the discount, the savings were used to significantly increase the potency of the Neprinol formulation. Subsequently after leaving Specialty enzymes Neprinol is now rated at a whopping 36,000 FU's. Serracor is substantially inferior to Neprinol in activity, but costs roughly the same. Serracor sells for $20 less than Neprinol but is only 66% as potent. Serracor would be considered an equivalent investment to Neprinol, but only if it sold for $97 for a 300 capsule bottle.
Enzyme testing reveals Serracor to be inferior to Neprinol
Assay test results confirmed their suspicion. Originally Neprinol was developed at 500mg per capsule with a rated activity strength of no less than 15,000 FU's or Fibrinolytic Units. Assay testing in several categories reviled a 33% decrease in activity. Each capsule averaged less than 10,000 FU's and they were under-weighted at only 475mg. In summation the potency of the product had been decreased by 33% and an additional 5% of the actual material was missing from every capsule.
Speciality Enzymes aka (AST Enzymes) had been skimming a substantial amount of enzymes from the formula and pocketing the added profits at a cost to the consumer and Arthur Andrew Medical. It is these unethical and shady business practices that cost them, the Neprinol account and any future business agreements with Arthur Andrew Medical. Arthur Andrew Medical was originally willing to pay substantially more for the inclusion of Specialty Enzymes trademarked enzymes in their Neprinol formula. Prior to the indecent president and CEO of Specialty Enzymes Vic Rathi called Arthur Andrew Medical to inform them that he would be raising prices by 5% even during economic recession. His reasoning was that the dollar was currently worth less, and he would need to increase costs to compensate. Arthur Andrew Medical had substantially increased their raw material purchasing with Specialty Enzymes over the years and had received 1-2% discounts for higher volume purchases. A 5% increase on much larger purchases would more than negate any previous discounts in a matter of months. Specialty Enzymes whether it be greed or a lack of available liquid assets did not accept any credit terms or negotiate any leniency for the price adjustment and insisted on an upfront 50% cash payment 8-10 weeks prior to delivery of materials. Arthur Andrew Medical estimates the dilution of the Neprinol formula coupled with the removal of 5% of the actual materials equated to a theft of up to $300k over several runs. Arthur Andrew refunded several thousand dollars to dissatisfied customers in 2009 in an attempt to right the wrong. Arthur Andrew also issued an official apology letter to affected customers and offered significant discounts on the purchase of new Neprinol bottles once the formula had been restored to its original label claims.
Rather than demand that Specialty Enzymes immediately restore Neprinol to its original formula and refund the material costs, Arthur Andrew subsequently took its Neprinol formulation elsewhere, contracting with several highly reputable Japanese enzyme manufacturers and a few local suppliers in the US and Canada. The loss of business for Specialty Enzymes delivered a significant blow to their yearly enzyme sales. Later that year Specialty Enzymes decided to manufacture and market their own systemic enzyme formula. They named it Serracor and they claim it’s the original Neprinol formula. In fact, it is not the original Neprinol formula, but rather the diluted knock-off that many of Arthur Andrew Medical's customers originally complained about. Arthur Andrew Medical recently tested Serracor for potency. Assay tests revealed their suspicion, the FU rating was only 2/3 of its labeled rating. Consumers can easily tell the difference simply by weighing a capsule of Serracor, each capsule is on average only 475mg of the label that reads 500mg. Arthur Andrew was able to save a significant amount of money contracting new, more competitive and honest raw material manufactures.
Instead of pocketing the discount, the savings were used to significantly increase the potency of the Neprinol formulation. Subsequently after leaving Specialty enzymes Neprinol is now rated at a whopping 36,000 FU's. Serracor is substantially inferior to Neprinol in activity, but costs roughly the same. Serracor sells for $20 less than Neprinol but is only 66% as potent. Serracor would be considered an equivalent investment to Neprinol, but only if it sold for $97 for a 300 capsule bottle.
Enzyme testing reveals Serracor to be inferior to Neprinol
This graph demonstrates fibrinolytic (activity testing) for the most common brands of systemic enzymes. Serracor manufacturers are claiming 15,000 FU's per capsule (500mg). Actual testing reveals only about 10,000. Testing reveals, Serracor meets only 2/3 of its advertised strength while Neprinol exceeds its label claims by over 6,400 FU's.
